Upjohn EESV — China registrations and re-registration filing lines
6 certificates in the NMPA overseas-manufactured drug database (境外生产药品库), snapshot 2026-06-28. Earliest filing line: 2028-12-26.
| Approval number | Product | Certificate expires | Filing line (Art. 82) |
|---|---|---|---|
| 国药准字HJ20190071 | Sildenafil Citrate Orodispersible Tablets 枸橼酸西地那非口崩片 | 2029-06-26 | 2028-12-26 |
| 国药准字HJ20200002 | Sildenafil Citrate Tablets 枸橼酸西地那非片 | 2029-09-28 | 2029-03-28 |
| 国药准字HJ20150619 | Lyrica 普瑞巴林胶囊 | 2029-11-25 | 2029-05-25 |
| 国药准字HJ20150620 | Lyrica 普瑞巴林胶囊 | 2029-11-25 | 2029-05-25 |
| 国药准字HJ20150622 | Lyrica 普瑞巴林胶囊 | 2029-11-25 | 2029-05-25 |
| 国药准字HJ20150623 | Lyrica 普瑞巴林胶囊 | 2029-11-25 | 2029-05-25 |
Under the Provisions for Drug Registration (药品注册管理办法) Art. 82, an application to renew an overseas-manufactured drug registration is filed with the Center for Drug Evaluation no later than 6 months before the certificate expires; the filing line column is that arithmetic applied to the expiry cell. Art. 84(1): a certificate with no application by expiry is not re-registered and is cancelled at expiry. Every figure is taken from the public NMPA database as of 2026-06-28, or computed from it. Registration data changes; the NMPA portal governs. This page states no view on whether any of these products' Domestic Responsible Person (境内责任人) arrangements meet NMPA Announcement No. 137 — that cannot be determined from a public entry.